ANVS

Annovis Bio, Inc.
CAPPED RATING

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer\'s disease (AD), Parkinson\'s disease (PD) and Alzheimer\'s in Down Syndrome (AD-DS). The Comapny\'s believes that it is the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The Company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. The Company has two ongoing Phase 2a studies: one in AD patients and one in both AD and PD patients.

Annovis Bio, Inc. (ANVS) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (C+); its weakest is Profitability (D-). The rating has held at C- for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.7 / 5.0
Profitability
D-
Factor Score 0.9 / 5.0
Momentum
D-
Factor Score 1.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.0
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -58.3%
Price Return 12M -67.3%
Catalyst Signal 0.00
Market Cap $32.3M
TTM Revenue N/A
Price / Sales N/A
ROE N/M

Historical Factor Score Progression

Held C- for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.5) C+ (2.7) D- (0.9) D- (1.0) C+ (2.6) C- (1.9)
2026-11-10 C+ (2.5) C+ (2.6) D- (0.9) D- (1.1) C+ (2.6) C- (2.0)
2026-11-03 C+ (2.5) C+ (2.5) D- (0.9) D (1.2) C+ (2.7) C- (2.0)
2026-10-27 C+ (2.5) C+ (2.5) D- (1.0) D (1.4) C+ (2.6) C- (2.0)
2026-10-20 C+ (2.5) C (2.5) D- (1.0) D (1.2) C+ (2.6) C- (2.0)
Page 1 of 5